Press Releases

Russo Partners Teams with Medovex to Highlight Medical Technology Innovation with DenerveX System for Treatment of Chronic Back Pain

NFL Broadcaster, Agency's Sports-Health Alliance Leader Solomon Wilcots Kicks Off Campaign with Surgeon Interviews at International Spine Meetings

NEW YORK, Nov. 13, 2017 /PRNewswire/ -- Russo Partners LLC and Medovex Corp. (NASDAQ: MDVX) have teamed to call attention to the need for new treatments for chronic back pain and the Company's innovative solution known as the DenerveX® System. Currently approved for use outside of the U.S., DenerveX is a new device designed to enable doctors to provide patients with enduring relief of back pain caused by Facet Joint Syndrome.

The Medovex public relations initiatives include an extensive video campaign featuring spine surgeons worldwide. Wilcots, an NFL broadcaster, former professional football player and leader of Russo Partners' Sports-Health Alliance, recently interviewed doctors at the EUROSPINE 2017 annual meeting in Dublin and the North American Spine Society (NASS) conference in Orlando, where he also taped a demonstration of the DenerveX System in use in a surgical cadaver lab. Russo Partners and Medovex will integrate the content into ongoing social and traditional media initiatives this quarter as Medovex continues its country-by-country roll-out of the medical technology.

"Solomon has the natural ability to bring professionals together and craft medical stories in a natural and impactful manner," said Patrick Kullmann, president and COO of Medovex. "We look forward to using the output of his work to increase the visibility and awareness of what we are doing at Medovex to transform how surgeons and pain management physicians treat a common source of chronic back pain. This is a meaningful change with our DenerveX system that is focused on long-term relief."

Wilcots added, "Chronic back pain, including that caused by Facet Joint Syndrome, is common among former professional athletes. The opportunity presented by the DenerveX System is one of giving people back quality of life without reliance on prescriptive pain relief medicines. This is exciting technology about which physicians were eager to speak with me and share their perspectives on how it will change their practices and patients' lives. We will continue with these initiatives throughout 2018."

The DenerveX System is a non-addictive opioid drug alternative capable of restoring a patient to a more normal and active lifestyle. It was designed by medical professionals for medical professionals to enhance a patient's quality of life. Using highly differentiated technology, the DenerveX System denervates and removes capsular tissue from the facet joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and radio frequency ablation treatment on the facet joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint. To learn more about the DenerveX System, visit http://medovex.com/us/denervex-system/.

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in countries worldwide, including the U.S. and countries in the EU. This condition affects millions of people each year, and current treatment options are generally temporary with no proven long-lasting option.

About Medovex

Medovex Corp. was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with Facet Joint Syndrome at significantly less cost over time than currently available options. To learn more about Medovex, visit www.medovex.com.

About Russo Partners' Sports-Health Alliance

The Sports-Health Alliance is an award-winning public relations service at the intersection of health, medicine and sports. Launched by Russo Partners in 2017, this offering leverages the agency's inside access to athletes, broadcasters and sports business leaders who have a shared passion with their clients for a disease or treatment. The Alliance was cultivated over a two-year span and involves Russo Partners' Team Leader Solomon Wilcots. Visit https://russopartnersllc.com/services/sports-health-alliance/ for more information.

About Russo Partners

Since 1988, Russo Partners, formerly Noonan/Russo Communications, has provided public and investor relations and corporate communications services to both emerging and established healthcare and technology-centric companies worldwide. The agency's staff is comprised of senior executives with extensive backgrounds in science, medicine, finance and communications. Visit www.russopartnersllc.com for more information. 

CONTACT INFORMATION

Medovex Corp.
Jason Assad
470-505-9905
Jassad@medovex.com

GLOBAL MEDIA CONTACTS

David Schull
Russo Partners LLC
212-845-4271 (office)
858-717-2310 (mobile)
David.schull@russopartnersllc.com

Caroline Cunningham
Russo Partners LLC
212-845-4292 (office)
203-969-4308 (mobile)
Caroline.cunningham@russopartnersllc.com

View original content:http://www.prnewswire.com/news-releases/russo-partners-teams-with-medovex-to-highlight-medical-technology-innovation-with-denervex-system-for-treatment-of-chronic-back-pain-300554402.html

SOURCE Russo Partners, LLC

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.